Drug Trial Radar · NCT05712538
Safety, Tolerability, and Pharmacokinetics of ARCT-032 in Healthy Adult Subjects and Adults With Cystic Fibrosis.
Last checked: Nov 19, 2026Latest source record: Nov 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
39
Actual
Start
Feb 15, 2023
Primary completion
Jul 29, 2024
Study completion Jul 29, 2024
Sponsor
- Lead sponsor
- Arcturus Therapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Novotech CRO
- First posted
- Feb 3, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Determine the safety, tolerability and pharmacokinetics of single doses of ARCT-032 in healthy adult subjects (Phase 1) and of two doses in Adults with Cystic Fibrosis (Phase 1b).
Conditions
- Cystic Fibrosis
Interventions
ARCT-032Drug
ARCT-032 is messenger RNA (mRNA) coding for cystic fibrosis transmembrane conductance regulator (CFTR) protein, formulated in a lipid nanoparticle (LNP).
PlaceboOther
Normal saline
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence, severity and dose-relationship of AEsTime frame: 4 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
New Zealand Clinical Research
Christchurch, New Zealand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.